Jump to:
Parker Elliot joined the corporate department of Ropes & Gray’s Boston office in 2021. Prior to joining the firm, Parker was an associate in the technology group of a premier Canadian law firm.
Parker advises biotechnology, pharmaceutical, medical device, and technology companies in strategic transactions including license and collaboration agreements, mergers and acquisitions, supply and distribution arrangements, and other commercial transactions in which intellectual property is a key consideration.
Experience
Licensing and Strategic Transactions
- Represented Ginkgo Bioworks, a leading platform for cell programming and biosecurity, in numerous transactions, including:
- in the acquisition of AgBiome’s platform assets in agricultural biologics; and
- in its multi-product collaboration to develop and optimize microbial strains using Ginkgo’s proprietary foundries and technology.
- Represented a pharmaceutical company in negotiating option agreements with biotechnology company focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology.
- Advised Acumen Pharmaceuticals in a global non-exclusive collaboration and license agreement with Halozyme Therapeutics.
- Advised HUTCHMED (China) Limited in a $1.13 billion exclusive worldwide license to Takeda to develop, manufacture and commercialize HUTCHMED's colorectal cancer treatment, fruquintinib, outside of mainland China, Hong Kong and Macau. At signing, this was the largest deal in China history for small molecules discovered and developed by China biotechnology companies.
- Advised Goldfinch Bio, Inc. in an exclusive global license to Karuna Therapeutics to develop, manufacture and commercialize Goldfinch’s therapeutic candidates as potential treatments for various psychiatric and neurological conditions, which involved $15 million in upfront payments and up to $520 million in milestone payments for each licensed therapeutic TRPC4/5 program candidate.
- Advised Cullinan Oncology, Inc. in an exclusive license agreement with Harbour BioMed for the development and commercialization rights to Harbour BioMed’s clinical stage bispecific immune activator, which included $25 million in upfront payments and up to $563 million in potential milestone payments.
- Advised a biotechnology company in a series of strategic intercompany license and service agreements to facilitate the offshoring of certain IP assets.
Mergers & Acquisitions
- Advised Partners Group, one of the largest firms in the global private markets industry, on its acquisition – on behalf of its clients – of a majority stake in FairJourney Biologics ("FairJourney"), a leading antibody discovery Contract Research Organization (CRO), from GHO Capital Partners.
- Represented MACOM Technology Solutions Holdings, Inc., a supplier of semiconductor products, in the completion of its acquisition of the radio frequency (RF) business of Wolfspeed, Inc.
- Advised Social Leverage Acquisition Co. in its $1.25 billion merger with W3BCLOUD, a storage and compute infrastructure provider for Web3.
- Advised Kohlberg & Co. and its portfolio company MarketCast in the add-on acquisition of Phoenix Marketing International, a leading research and analytics provider that specializes in advertising measurement.
- Advised GHO Capital Partners and Genesis Research in the acquisition of Market Access Transformation, a leading provider of technology-enabled payer research platforms.